Vitásková Denisa

Vitásková Denisa's picture
Academic Title: MUDr.

Publications (Impact Factor Journals):

  • [4]
    ŠTUDENTOVÁ, H., D. VITÁSKOVÁ a B. MELICHAR. Lenvatinib for the treatment of kidney cancer. Expert Review of Anticancer Therapy. 2018, 18(6), 511-518. ISSN 1473-7140. IF: 2.2012. PMID: 29737893
  • [3]
    ŠTUDENTOVÁ, H., D. VITÁSKOVÁ a B. MELICHAR. Safety of mTOR inhibitors in breast cancer. Expert Opinion on Drug Safety. 2016, 15(8), 1075-85. ISSN 1474-0338. IF: 3.439. PMID: 27210004
  • [2]
    ŠTUDENTOVÁ, H., D. VITÁSKOVÁ, V. ŠRÁMEK, J. INDRAKOVA, T. ADAM, J. JURANOVA, P. PETROVA, L. KUJOVSKA KRCMOVA, E. PESKOVA, D. SOLICHOVA, H. KALÁBOVÁ a B. MELICHAR. Correlations of neutrophil-to-lymphocyte, lymphocyte-to-monote and platelet-to-lymphocyte ratios with biomarkers of atherosclerosis risk and inflammatory response in ptients with a history of breast cancer. Pteridines. 2015, 26, 161-172. ISSN 0933-4807. IF: 0.452.
  • [1]
    MELICHAR, B., H. ŠTUDENTOVÁ, D. VITÁSKOVÁ, V. ŠRÁMEK, L.K. KRCMOVA, E. PESKOVA, D. SOLICHOVA, H. KALÁBOVÁ, A. RYSKA, K. HRUZOVA a R. HAVLÍK. Association of urinary neopterin, neutrophil-to-lymphocyte, lymphocyte-to-monocyte and platelet-to-lymphocyte ratios with long-term survival of patients with breast cancer. Pteridines. 2016, 27(3-4), 59-65. ISSN 0933-4807 . IF: 0.621.